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Abstract: The mimicking of physiological conditions is crucial for the success of accurate in vitro 
studies. For inhaled nanoparticles, which are designed for being deposited on alveolar epithelium 
and taken up by macrophages, it is relevant to investigate the interactions with pulmonary 
surfactant lining alveoli. As a matter of fact, the formation of a lipid corona layer around the 
nanoparticles could modulate the cell internalization and the fate of the transported drugs. Based 
on this concept, the present research focused on the interactions between pulmonary surfactant and 
Solid Lipid Nanoparticle assemblies (SLNas), loaded with rifampicin, an anti-tuberculosis drug. 
SLNas were functionalized with a synthesized mannosylated surfactant, both alone and in a blend 
with sodium taurocholate, to achieve an active targeting to mannose receptors present on alveolar 
macrophages (AM). Physico-chemical properties of the mannosylated SLNas satisfied the 
requirements relative to suitable respirability, drug payload, and AM active targeting. Our studies 
have shown that a lipid corona is formed around SLNas in the presence of Curosurf, a commercial 
substitute of the natural pulmonary surfactant. The lipid corona promoted an additional resistance 
to the drug diffusion for SLNas functionalized with the mannosylated surfactant and this improved 
drug retention within SLNas before AM phagocytosis takes place. Moreover, lipid corona formation 
did not modify the role of nanoparticle mannosylation towards the specific receptors on MH-S cell 
membrane. 
Keywords: solid lipid nanoparticles; mannosylated surfactant; tuberculosis; inhalation; active 
targeting; pulmonary surfactant 
 
1. Introduction 
Inhalable powder formulations of drugs intended for immediate biological actions within 
alveolar macrophages (AM) entail engineering techniques that enable drug emission by Dry Powder 
Inhaler (DPI) devices, deposition onto alveolar epithelia, and transport into AM [1–3]. Actually, most 
drugs for the treatment of intramacrophagic bacterial infections such as tuberculosis are poorly 
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soluble in water; in this case, their aerosol formulations must be produced by using drugs in the solid 
state. Untreated drugs exhibit rarely properties suitable for both DPI and targeting to AM, in which 
Mycobacterium tuberculosis resides. Therefore they fail to both reach alveolar epithelium and penetrate 
AM effectively [4,5]. Among the particle engineering techniques, the recourse to micro- or 
nanoparticulate drug carriers has the potential to facilitate drug macrophage uptake while 
maintaining particle respirability and drug dosing accuracy. For these reasons, several potential 
inhaled powders have been successfully designed using particulate formulation approach. Moreover, 
particulate formulations are suitable for inserting specific molecules at the particle surface to promote 
receptor-mediated AM endocytosis [6]. Macrophage mannose receptors (MR), overexpressed on 
infected AM, can recognize particles functionalized with mannose residues on their surface, 
promoting their internalization [7,8]. However, the targeting moieties must remain associated on the 
particle surface also in biological environments without losing their functionality until the target is 
reached. 
The alveoli and consequently AM are lined by the alveolar lining fluid (ALF) that is generated 
by the alveolar epithelial cells. It is essential for maintaining fundamental lung functions (protection, 
immune response, and reduction of surface tension at the air-liquid interface) [9,10]. ALF is 
constituted by the pulmonary surfactant, a surface-active phospholipid/protein mixture mainly 
constituted by lipids [11–13]. Pulmonary surfactant can be adsorbed by particulate matter producing 
a bio-nano interface referred as protein/lipid corona. Although most of studies focused on the 
protein/lipid corona formed by interactions of nanoparticles with plasma, more recently some 
attention has been paid also to other biological fluids such as ALF [13–22]. Unlike the protein corona 
formed in plasma, that is attributable to interactions between nanoparticles and proteins, the corona 
layer formed around inhaled nanoparticles proved to differ markedly, because it preserves a lipid 
composition regardless of nanoparticle surface properties. This finding was related to the high 
content of phospholipids (about 80–90%) present in the pulmonary surfactant [12,19]. Such a corona 
formed around the particles is described to be affected by particle size, shape, surface charge, 
covalent/coordinate bonding or hydrogen bonding propensity, hydrophobicity, and surface 
functional groups as well as environment composition and exposure duration. Among these 
parameters, the surface hydrophobicity and charge density play a more significant role [23,24]. It is 
known that corona can deeply influence the interaction of nanoparticles with cells and determine not 
only the nanoparticle fate, but also their properties such as aggregate formation, pulmonary 
clearance, receptor-mediated transport, and drug release behavior [15,16,18,19,25–27], although some 
discordant results have also been reported. For example, corona layer was found to impair 
nanoparticle adhesion onto cell surface or to decrease particle uptake by macrophages [16,28,29]. On 
the other hand, some studies reported an improved cell internalization [14,30–32]. Therefore, the 
implications of corona layer on AM targeting using inhalable carriers remain still an open issue that 
needs to be further explored. 
Within this context, respirable Solid Lipid Nanoparticle assemblies (SLNas) loaded with 
rifampicin, a clinically useful anti-tuberculosis drug, were previously produced as inhaled 
pulmonary tuberculosis treatment using DPI device. To this aim, accepted excipients for DPI 
formulations were processed through an optimized methodology that avoids organic solvents 
[33,34]. The prototypes were functionalized by means of newly synthesized mannosylated 
surfactants as AM receptor-specific targeting agents anchored on SLNas surface without the need of 
chemical reactions [5]. The focus of the present research was the investigation of the interactions 
between pulmonary surfactant and SLNas functionalized with solely a mannosylated surfactant and 
also in a blend with the natural bile acid surfactant sodium taurocholate. The effect of such 
interactions on in vitro drug release and internalization ability by murine alveolar macrophages MH-
S cell line was investigated and compared with non-mannosylated SLNas.  
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2. Materials and Methods 
2.1. Materials 
Palmitic acid (PA) from Fluka Chemie (Buchs, Switzerland), cholesteryl myristate (CM) from 
TCI Europe (Zwijndrecht, Belgium), polyoxyethylene polyoxypropylene block copolymer (Lutrol 
F127) (F127) from BASF (Ludwigshafen, Germany), sodium taurocholate (ST) and rifampicin (RIF) 
from Alfa Aesar (Ward Hill, MA, USA) were purchased. The mannosylated surfactant hexadecanoic 
acid (aminoethyl α-D-mannopyranoside)amide (MS) was synthesized as previously reported [5] and 
used as functionalizing/surfactant agent. Simulated Lung Fluid type 3 (SLF) at pH 7.4, used for in 
vitro drug release, was prepared accordingly to Marques [35]. Curosurf, used for lipid corona 
determination, was kindly donated by Chiesi Farmaceutici (Parma, Italy). For HPLC analysis, methyl 
parahydroxybenzoate, used as internal standard (IS), was purchased from Carlo Erba Reagenti 
(Milan, Italy). For cell culture assays, MH-S cell line was purchased from IZSLER (Brescia, Italy). For 
cell medium, RPMI 1640, fetal bovine serum (FBS), L-Glutamine, penicillin–streptomycin (P/S), and 
phosphate-buffered saline (PBS), and trypsin-EDTA from PAN-Biotech (Aidenbach, Germany), D-
mannose and dimethyl sulfoxide (DMSO) from VWR International (Milan, Italy) were purchased. All 
the other chemicals were of analytical grade. 
2.2. Methods 
2.2.1. SLNas Preparation 
SLNas were prepared by the melt emulsification technique. In practice, the lipid phase 
containing 92.5 mg PA, 42.5 mg CM, and 45 mg RIF was melted at 85 °C and emulsified in 10 mL 
MilliQ water containing the functionalizing/surfactant agent MS (0.1%) alone or in a blend with ST 
(0.05%) to prepare the samples SLNas/MS or SLNas/MS-ST, respectively. Control samples in which 
MS was not included, SLNas/ST and SLNas/F127, were obtained by using 0.2% ST and 1% F127, 
respectively. The two phases were mixed by ultrasonification (Branson Sonifier® SFX150, Emerson 
US, St. Louis, MO, USA) (150 W for 3 min) and rapidly cooled in ice, under magnetic stirring (15 min). 
The resulting particle suspension was added with MilliQ water (300 mL) and purified by a dialysis 
membrane (MWCO 12–14,000 Da; Medicell International Ltd., London, UK) for 30 min to remove the 
non-encapsulated drug and the excess of functionalizing/surfactant agents. Dialysis time was 
selected in preliminary studies as the best compromise between drug retaining within SLNas and the 
surfactant removal. Then, the samples were water diluted 1:55, rapidly frozen at −70 °C in a dry 
ice/acetone cooling bath, and then freeze-dried (Lio 5P, CinquePascal, Milan, Italy), to obtain a final 
powder according to the method previously optimized [34].  
2.2.2. Morphology, Size, and Z-Potential 
SLNas morphology was evaluated by Scanning Electron Microscopy (SEM, Nova NanoSEM 450, 
Fei, Eindhoven, The Netherlands) using TEM mode with STEM detector (30 kV). Carbon/copper TEM 
grids were soaked in properly diluted SLNas water suspension, dried and coated with carbon under 
vacuum (carbon coater, Balzers CED-010, Oerlikon Balzers, Balzers, Liechtestein). The obtained 
images were analyzed by an image software (ImageJ version 1.32J, Java, Bethesda, MD, USA) to 
measure circularity parameter where the value of a circle is 1, whereas values less than 1 indicate 
irregular particles. Size, polydispersity index (PDI), and Z-potential values were measured by using 
Photon Correlation Spectroscopy (PCS) (Zetasizer version 6.12, Malvern Instruments, 
Worcestershire, UK) equipped with a 4 mW He-Ne laser (633 nm) and a DTS software (Version 5.0). 
The samples were suspended in MilliQ water for Z-potential analyses and in cell medium for size 
and PDI determinations. Before the tests, the samples were vortexed for 1 min and sonicated for 3 
min in ultrasonic bath (USC200TH, VWR International, Milan, Italy) at 37 °C. Each sample was 
analyzed three times. 
Pharmaceutics 2019, 11, 508 4 of 20 
 
2.2.3. Density, Carr’s Index, and Specific Surface Area 
The bulk density of SLNas was determined by measuring the volume of a weighed powder 
amount in a graduated cylinder. Tapped density was determined by measuring the volume of the 
tapped powder until no further volume change was observed, according to Ph. Eur. 9.0 [36]. Density 
data have been used to determine Carr’s Index (compressibility index). True density was determined 
on the powder using a helium pycnometer (AccuPyc 1330, Micromeritics Inc., Norcross, GA, USA). 
Specific BET (Brunauer, Emmett and Teller) surface area was determined using the Gemini 2360 
instrument from Micromeritics (nitrogen gas). Moreover, a size of SLNas powder, named d(BET), 
was determined using true density (ρ) and BET specific area as follow: d(BET) = 6/(ρ·AreaBET). All the 
measurements were performed in triplicate. 
2.2.4. Thermal Analysis 
In order to investigate the effect of the preparation process on SLNas physical state, rifampicin, 
SLNas samples as well as their physical mixture, prepared at the same drug/lipid ratio as SLNas, 
were analyzed using simultaneous thermogravimetry and differential scanning calorimetry 
(TG/DSC) (NETZSCH mod. STA409, Netzsch-Gerätebau GmbH, Selb, Germany). A second heating 
run, in order to simulate SLNas preparation thermal conditions, was performed on the physical 
mixture. The temperature range used was 20–800 °C with a heating gradient of 10 °C/min. The 
analyses were performed in triplicate. 
2.2.5. X-Ray Powder Diffraction 
X-Ray Powder Diffraction (XRPD) data were collected in the 2θ range 3–50° using a θ/θ 
diffractometer (X’Pert PRO PANalytical, Monza, MB, Italy, Cu Kα radiation) equipped with a real-
time multiple strip detector. The incident beam optics included divergence and anti-scattering slits 
(0.5°) as well as a soller slit (0.02 rad). The diffracted beam passed through a soller slit (0.02 rad), a Ni 
filter and an antiscatter blade before arriving to the detector. Samples were gently ground and 
sprinkled on a zero-background sample holder (single crystal silicon).  
2.2.6. X-ray Photoelectron Spectroscopy 
The experiments by means of X-ray Photoelectron Spectroscopy (XPS) were carried out in ultra-
high vacuum at a base pressure of 10−9 mbar. X-ray photoemission data were recorded with a VG 
Microtech Clam2 hemispherical electron analyzer operated at constant pass energy. Overview scans 
were acquired with a pass energy of 100 eV (2 eV resolution), while higher resolution spectra of single 
elements were acquired with a pass energy of 35 eV (0.7 eV resolution). X-ray photoemission was 
carried out with non-monochromatic Mg Kα photons (hν = 1253.6 eV) from a Vacuum Generators 
XR3 dual anode source operated at 15 kV, 18 mA. The Mg Kα satellite lines and the background 
(Shirley or linear type) were subtracted from the acquired spectra. The spectra were fitted with Voigt 
components for quantitative analysis. Following a standard procedure [37], from the peak areas and 
considering appropriate tabulated atomic sensitivity factors for the different peaks, a quantitative 
evaluation of the elements present at SLNas surface was then performed. 
2.2.7. Wettability  
The wettability was determined on SLNas tablets obtained by direct compression of 100 mg 
sample using a hydraulic press (100 kg/cm2, 30 s, 40 mm diameter punches). The direct measurement 
of the contact angle, the tangent angle at the contact point between the water drop and the tablets, 
was carried out by the sessile drop method. In practice, drop profiles enlarged by a telescope were 
captured and the angles on both sides of the liquid drop were measured at time zero. The 
determinations were carried out in triplicate from three different batches. 
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2.2.8. Drug Loading and Encapsulation Efficiency 
SLNas drug loading, expressed as % w/w, was determined by HPLC analysis as previously 
described [34]. Briefly, analyses were carried out on a reversed-phase column (RP-18e, 125 × 4 mm, 
5.0 μm) thermostatted at 30 °C and protected by a guard column (4.0 × 4.0, 5.0 μm) (Purospher, Merck, 
Darmstadt, Germany). The mobile phase consisted of methanol/0.02 M sodium acetate buffer (pH 
5.0) using a gradient elution with a flow rate of 0.9 mL/min; the column eluates were monitored at 
254 nm. Calibrators containing an internal standard (IS) and increasing RIF concentration were 
analyzed in triplicate; the peak-area ratio of RIF to IS was plotted against the RIF concentration to 
calculate the calibration curve by the method of least squares. For SLNas samples, exactly weighed 
aliquots, added with the IS solution and methanol, were heated at 50 °C for 30 min, filtered and 
analyzed by RP-HPLC (n = 3). RIF content was calculated by interpolation of the calibration curve 
and the encapsulation efficiency (EE) was estimated by comparing the percentage of RIF entrapped 
in SLNas (actual drug loading) compared to the initial RIF amount used in SLNas preparation 
(theoretical drug loading). Data were averaged on three determinations. 
2.2.9. Aerodynamic Diameter  
SLNas aerodynamic diameter (da), defined as the diameter of a sphere of unit density, was 
estimated by the following relationship:  
dୟ = d୴ ඨ
ρ୲ୟ୮୮ୣୢ
χρ଴  
where dv is d(BET), ρ0 is the unit density (of spherical calibration particles), ρtapped is the particle 
tapped density and χ is the dynamic shape factor, defined as circularity.  
2.2.10. Respirability 
In vitro powder respirability was assessed using Glass Twin Impinger (GTI) (Disa, Milan, Italy). 
SLNas samples were loaded (about 30 mg), equally distributed, into 3 capsules (V-Caps Capsugel, 
Morristown, NJ, USA) and aerosolized using a RS01 device (Plastiape, Lecco, Italy) with a flow rate 
of 55 L/min, capable of producing a pressure drop of 4 kPa over the inhaler. Considering RIF 
solubility, methanol was used as the collection liquid, of which 7 and 30 mL were inserted into the 
two GTI stages (stages A and B). The vacuum was applied for 4 s to obtain 4 L of air through the 
instrument during the experiment. After simulation, drug traces within the capsule/device (stage D) 
and all the other stages were washed with methanol and RIF was quantified spectrophotometrically 
(Lambda 3B Perkin-Elmer, Waltham, MA, USA) at the wavelength of 475 nm. Unlike SLNas size in 
stages D and A estimated >6 μm, the particles captured in stage B were considered as the fine particle 
fraction <6 μm. All the experiments were performed in triplicate. 
2.2.11. Lipid Corona Formation 
In vitro lipid corona formation around SLNas was evaluated by size and surface charge analysis 
(1) and also by Energy Dispersive X-ray (EDX) analysis (2). 1) Size, PDI, and Z-potential of pure 
Curosurf and SLNas, before and after treatment with Curosurf, were determined using PCS. 
Curosurf was diluted at 1.5 mg/mL using a saline solution and added to 1 mg/mL of SLNas samples 
under magnetic stirring (200 rpm) at 37 °C for 1 h. The size was measured and compared with that 
measured on the samples suspended in saline solution. All the determinations were carried out in 
triplicate on properly MilliQ water diluted samples. 2) The elemental composition was determined 
by EDX analysis (INCA 350, Oxford Instruments, Abingdon, UK) coupled with ESEM (Quanta 200, 
FEI Company, Oxford Instruments, Abingdon, UK) for pure Curosurf and SLNas samples before and 
after treatment with Curosurf. Sample suspensions were dried on ESEM stubs before analyses. X-ray 
emission from Ka or Kb levels of the atoms C, O, Na, P, S, and Cl were recorded. The EDX spectra 
expressed as the plots of X-ray counts vs. element energy peak and semi-quantitative results, 
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expressed as relative weight percentage of the elements, were recorded under the following 
conditions: low vacuum (0.70 Torr), accelerating voltage 20 kV, spot size 5, element detection limit 
~0.05 wt%, spatial resolution 0.1 μm, total spectrum counts >250,000, accuracy within ±5% relative 
errors by reference to standards. The semi-quantitative analysis was determined by using the Φ(ρz) 
method [38]. The reported data were averaged over three determinations for each sample.  
2.2.12. In Vitro Drug Release 
In vitro RIF release from SLNas was performed in sink conditions by placing approximately 30 
mg of SLNas powder suspended in 2 mL SLF alone or with Curosurf (1:1.5 SLNas:Curosurf ratio) 
within a dialysis membrane (cut off 12,000/14,000 D) and immediately soaked in 30 mL of SLF at 37 
°C. The equipment was maintained in darkness under gently magnetic stirring to mimic the lung 
environment. Sample solutions were withdrawn at fixed time intervals and the initial volume 
restored. The solutions were analyzed spectrophotometrically (Lambda 3B Perkin-Elmer, Waltham, 
MA, USA) in triplicate at the wavelength of 475 nm. 
2.2.13. Cell Culture Assay  
Murine alveolar macrophages MH-S cell line were cultured under mixed condition in RPMI 1640 
medium supplemented with 2 mM L-glutamine, penicillin 100 UI/mL, 100 μg/mL streptomycin, and 
10% FBS in T75 flasks at 37 °C and 5% CO2. For cytotoxicity and uptake experiments, cells were 
seeded in 24-well plates at a density of 120,000 cells/well or in 100 mm Petri dish at a density of 
4,000,000 cells/Petri, respectively.  
2.2.14. Cytotoxicity Test  
MH-S cell line was seeded to evaluate the cytotoxicity of SLNas and pure RIF. Cells were 
incubated for 6 h with 1 mL of SLNas suspended in complete RPMI 1640 (0.125, 0.25, 0.5, and 1.0 
mg/mL particle dose), vortexed for 1 min, and sonicated in sonic bath at 37 °C for 3 min. Regarding 
RIF, cells were incubated with 10 μL RIF solution in DMSO at a drug concentration range of 10–200 
μg/mL for 24 h as recommended for antibiotic toxicity on macrophages [39] (10 μL DMSO as the 
control).  
Cell viability was estimated by MTT test using a multiplate reader (TecanGenios Pro with 
Magellan 6 software, MTX Lab Systems, Bradenton, FL, USA) at an optical density of 535 nm to 
monitor the formazan formation by metabolically viable cells. The test was performed in triplicate 
and the results were expressed as percentage of cell survival compared with the untreated cells. 
2.2.15. Intracellular RIF Determination  
MH-S cells were plated in a 100 mm Petri dish and incubated with SLNas suspensions at 0.25 
mg/mL for 0.5, 1, and 3 h. After incubation, adherent cells were detached from the plate by addition 
of trypsin-EDTA and joined to the suspended cell fraction. After washing with PBS, RIF embedded 
inside cells was extracted by treatment with methanol (1 mL). Drug concentration was determined 
spectrophotometrically at 475 nm and expressed as RIF percentage on the specific drug loading level 
of each sample batch. The reported data were averaged on three determinations of three different 
batches. 
2.2.16. MR Inhibition Study  
MH-S cells were seeded in a 100 mm Petri dish and treated for 2 h with 50 mM D-mannose to 
saturate the mannose receptor on macrophage membrane. Subsequently, cells were incubated with 
SLNas (0.25 mg/mL) for 0.5, 1, and 3 h. Then, cells were handled as described in the previous section 
for the intracellular RIF determination. Reported data were averaged on three determinations of three 
different batches. 
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2.2.17. Intracellular RIF Determination after Lipid Corona Formation  
MH-S cells were seeded in a 100 mm Petri dish with cell medium without FBS and treated with 
SLNas previously suspended in cell medium (0.25 mg/mL) with Curosurf at 1:1.5 ratio 
(SLNas:Curosurf) and sonicated in the ultrasonic bath for 10 min at 37 °C. The cells were incubated 
with the mixture for 0.5, 1, and 3 h. Then, cells were handled as described in the previous section for 
the intracellular RIF determination. Reported data were averaged on three determinations of three 
different batches. 
2.2.18. Statistical Analysis  
Data obtained were evaluated statistically using one-way analysis of variance (ANOVA). 
Significance was indicated by p < 0.05 (* p < 0.05; ** p < 0.01; *** p < 0.005). 
3. Results and Discussion 
Based on the satisfactory results already achieved by anchoring newly synthesized 
mannosylated surfactants to SLNas surface [5], the purpose of this study was to investigate if the 
pulmonary surfactant lining the alveolar surface could possibly form, due to its high content of 
phospholipids, a lipid corona around the nanoparticles that might nullify alveolar macrophage (AM) 
active targeting and make SLNas functionalization unnecessary. The investigation involved both 
mannosylated SLNas (SLNas/MS) and SLNas functionalized by MS in a blend with sodium 
taurocholate (SLNas/MS-ST) in order to modulate the mannose concentration on the nanoparticle 
surface. Indeed, ST itself can play a key role, since an activity as opener of tight junctions between 
alveolar epithelial cells has been described [40], although the definitive mechanism has not been fully 
elucidated yet. In addition, it is also noteworthy that mannose receptors (MR) bear a cystein-rich 
domain that recognizes sulfonic group. SLNas obtained by using ST (SLNas/ST) or F127 
(SLNas/F127), a non-ionic surfactant devoid of groups able to bind MR, were evaluated as the 
controls. 
3.1. SLNas Physico-Chemical Properties 
The study of inhaled particulate drug carriers for AM active targeting, intended to increase 
particle specificity for macrophages and internalization potential over the passive targeting, must not 
disregard the investigation of the physico-chemical features required to both reach alveolar region 
and be phagocytized by AM. Therefore, the obtained SLNas samples were characterized for 
morphology, size, surface charge, shape factor, physical state, wettability, surface properties, density, 
flowability, drug loading, drug release, and respirability performance.  
It is well known that the efficiency of an inhaled powder formulation to settle into the deep lung 
depends upon particle geometrical parameters (shape, morphology, and size) that affect the powder 
respirability as well as macrophage uptake [6]. The most commonly used particles for DPI device 
exhibit irregular shapes. In vitro inhalation studies indicated that elongated [41,42], needle-like [43], 
porous and wrinkle [44], as well as thin flaky shapes [45] can improve lung deposition properties 
owing to reduced particle interactions [46]. Concerning macrophage phagocytosis, particle shape has 
shown to affect cell uptake mechanism or rate, with roundness being a preferred characteristic 
compared to elongated or filamentous shapes [6,47,48]. All the obtained SLNas samples exhibited 
rounded micro-aggregates of nanoparticles having an irregular shape with tendency to roundness, 
as indicated by circularity values from 0.6 to 0.83, with 1 indicating perfect roundness (Figure 1, Table 
1). 
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Figure 1. Transmission electron microscopy images of the SLNas samples. 
Table 1. Physical characteristics of the SLNas samples (mean values ± SD). 
Physical Characteristics SLNas/MS SLNas/MS-ST SLNas/ST SLNas/F127 
Circularity 0.6 ± 0.1 a 0.83 ± 0.03 b 0.74 ± 0.07 ab 0.75 ± 0.06 ab 
Size (nm) 740 ± 85 a 309 ± 30 b 668 ± 25 a 408 ± 57 b 
PDI 0.60 ± 0.05 0.30 ± 0.02 0.46 ± 0.05 a 0.46 ± 0.05 a 
Z potential (mV) −35.2 ± 0.1 −40.5 ± 0.9 −55 ± 2 −15 ± 0.1 
d(BET) (nm) 730 ± 10 900 ± 20 1020 ± 50 a 1090 ± 20 a 
ρ true (g/cm3) 1.147 ± 0.001 1.1939 ± 0.0008 1.247 ± 0.002 1.1791 ± 0.0008 
ρ bulk (g/cm3) 0.048 ± 0.001 0.079 ± 0.001 0.031 ± 0.000 0.147 ± 0.005 
ρ tapped (g/cm3) 0.052 ± 0.001 a 0.086 ± 0.001 0.038 ± 0.000 a 0.29 ± 0.02 
Carr’s Index 9 ± 2 a 8 ± 2 a 17 ± 1 a 50 ± 8 
BET area (m2/g) 7.2 ± 0.10 5.6 ± 0.10 4.7 ± 0.20 a 4.67 ± 0.09 a 
da (nm) 210 288 231 676 
ab Among columns, means that have no superscript in common are significantly different from each other  
(p < 0.05). 
Particle size of the samples, measured by PCS and expressed as the mean diameter of the main 
class (>85%), was within the range of about 300 to 750 nm, where the larger size was shown for 
SLNas/MS and SLNas/ST compared with that for SLNas/MS-ST and SLNas/F127 (p < 0.05). The size 
measured on the samples in their solid state by means of the BET technique, d(BET), aimed to 
simulate the therapeutic use of powdered drug by means of a DPI device. The d(BET) values were 
within the range from about 700 nm, for SLNas/MS, to 1100 nm for all the other samples (p < 0.05). 
This size is considered proper for the deposition onto alveolar region and AM endocytosis [6]. The 
related PDI values ranged from 0.3 to 0.6, owing to the presence of minor populations in the range of 
2–5 μm (<15%), owing to a multimodal size distribution of the particle aggregates. The surface charge 
of all the samples was negative (from −15 to −55 mV). Considering that SLNas include the same lipid 
matrix, the largest negative values were reasonably imparted by the negatively charged MS and ST 
unlike what occurred with the non-ionic surfactant F127. Extent and rate of macrophage uptake are 
known to be directly related to particle net charge magnitude, with negatively charged surface being 
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more physiologically compatible than the positive ones [6]. Moreover, unlike particles bearing 
positive charges, negative surface charges showed to favor particle localization within lysosomes, in 
which Mycobacterium tuberculosis survives [49,50]. As regards SLNas density features, true density 
values ranged from 1.147 to 1.247 g/cm3, bulk density from 0.031 to 0.147 g/cm3, and the respective 
tapped density values from 0.038 to 0.29 g/cm3; SLNas/F127 exhibited the highest values of both bulk 
and tapped density among the samples. The increased tapped density compared to the bulk density 
values indicates the presence of inter-particle void spaces. Tapped density represents a pivotal 
parameter for both flowability and aerodynamic diameter required for a respirable powder. Indeed, 
particles having low tapped density can efficiently aerosolize from a DPI, resulting in a high 
respirable fraction of inhaled therapeutics [51]. Flowability values, expressed as Carr’s Index, were 
affected by SLNas surface decoration; in particular, MS provided excellent flow properties also in the 
presence of ST (Carr’s Index <10) [52]. Conversely, SLNas/ST and SLNas/F127 flowability resulted 
fair and very poor, respectively. The flow properties of a powder as well as its de-aggregation and 
aerosol performance can also be influenced by inter-particulate interactions related to the specific 
surface area, i.e. the surface area per unit mass. Such a parameter depends on both particle size and 
surface roughness of the powder [41,53]. The average values for BET specific surface area of the 
SLNas samples were found to be 5–7 m2/g. 
Aerodynamic diameters were calculated for all the SLNas samples on the basis of their shape, 
BET size, and density characteristics and found to be in the range of 210–676 nm. Despite the values 
should be higher than 0.5 μm to promote particle deposition onto the alveolar epithelium [46,54], the 
analysis of the respirability performance, which reflects also the degree of particle cohesiveness and 
de-aggregation, provided more reliable results. The percentage values of Emitted Dose (ED) and Fine 
Particle Fraction (FPF) were measured by GTI (Table 2) to define the suitability for the powder to be 
discharged during the air actuation by DPI and the fraction deposited into alveolar region. 
Mannosylated samples (SLNas/MS and SLNas/MS-ST) as well as SLNas/ST showed ED values >80%, 
that is the threshold required by the European Pharmacopoeia [55] and FPF data around or >40%, 
indicating adequate respirability performance for antibiotics administered by DPI [56]. Only 
SLNas/F127 did not comply with powder respirability requirements (about 70% ED and 12% FPF); 
this was probably due to its very poor flowability and/or lower surface charge, which led to greater 
cohesiveness and lower de-aggregation ability compared with the other samples. 
Table 2. Aerodynamic parameters of the SLNas samples provided by Glass Twin Impinger: Emitted 
Dose (ED) and Fine Particle Fraction (FPF). Mean values ± SD. 
SLNas Samples ED (%) FPF (%) 
SLNas/MS 87 ± 4 a 38 ± 5 a 
SLNas/MS-ST 84 ± 2 ab 41 ± 5 a 
SLNas/ST 83 ± 1 ab 53 ± 4 
SLNas/F127 72 ± 8 b 11.77 ± 0.01 
ab Among lines, means that have no superscript in common are significantly different from each other (p < 0.05). 
Particulate carriers must exhibit adequate respirability characteristics, but they also must ensure 
an adequate drug payload within them to achieve a therapeutic effect with a feasible dose inside the 
DPI. In addition, the carriers have to possess the ability to retain the drug before their phagocytosis 
by AM [57]. The obtained RIF loading levels and EE values were about 9% and 35%, respectively, 
without significant differences among the samples (p > 0.05) (Table 3).  
Table 3. Drug loading (DL) and encapsulation efficiency (EE) values of the SLNas samples. Mean 
values ± SD. 
SLNas Samples DL (%) EE (%) 
SLNas/MS 9.2 ± 0.2 36.8 ± 0.9 
SLNas/MS-ST 8.7 ± 0.2 34.9 ± 0.9 
SLNas/ST 8.9 ± 0.3 36 ± 1 
SLNas/F127 8.4 ± 0.8 34 ± 3 
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By considering that RIF was stable under the adopted preparation conditions, as previously 
demonstrated [34], EE values indicate that RIF leached partly from the lipid matrix into the 
continuous phase of the emulsion during the preparation process or dialysis phase, as monitored in 
preliminary studies. The loaded RIF was found in the amorphous state within all SLNas matrices, as 
demonstrated by DSC analyses (Figure 2).  
 
Figure 2. Simultaneous thermogravimetry (red line) and differential scanning calorimetry (blue line) 
of SLNas/MS (a), SLNas/MS-ST (b), SLNas/ST (c), SLNas/F127 (d), physical mixture (e), and 
rifampicin (f). 
Indeed, RIF characteristic endotherm at about 260 °C (Figure 2f) was present only in the physical 
mixture (Figure 2e). The thermal events of PA and CM, ranging from 50 to 70 °C, were observed in 
both SLNas and physical mixture thermograms and no modification occurred during the second 
heating run (data not shown). Thermogravimetric profiles revealed mass losses related to the 
degradation of SLNas components in the range of 200–600 °C. No mass losses around 100 °C, 
attributable to dehydration processes, were observed in the samples except for SLNas/ST, which 
showed a mass loss of about 4% (Figure 2c). RIF within SLNas lipid matrices was confirmed to be in 
an amorphous state by XRPD patterns. Unlike the physical mixture showing RIF characteristic peaks 
at 9.9°, 11.1°, and 19.9° 2θ, even if with decreased peak intensity, all diffractograms exhibited the 
typical peaks of the matrix components except for RIF peaks, regardless of the sample (Figure 3). 
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Figure 3. XRPD profiles of the SLNas samples in comparison with the physical mixture of SLNas 
components as well as pure rifampicin. 
XPS analysis and wettability measurements were carried out to determine the chemical nature 
provided by the functionalizing moieties on the SLNas surface. Concerning XPS analysis, a technique 
for analyzing 5 nm-thick surface layer of the sample, the obtained data indicate the quantitative levels 
of the elements present on the sample surface (Table 4). 
Table 4. SLNas surface elemental composition (relative percentage of C, N, O, S, and Na) evaluated 
by XPS analysis and wettability expressed in terms of contact angle (θ). 
SLNas Samples C O N S Na θ (deg) 
SLNas/MS 71 25.5 3.3 0.0 0.0 51 ± 5 
SLNas/MS-ST 82 15.0 2.3 0.3 0.2 32 ± 4 
SLNas/ST 89 8.4 1.1 0.7 0.6 37 ± 8 
SLNas/F127 86 13.3 0.6 0.0 0.0 79 ± 2 
Carbon (C1s), oxygen (O1s), and nitrogen (N1s), this latter belonging to MS, ST, and RIF, were 
found on the surface of all the samples, whereas sulphur (S2p) and sodium (Na1s) were detected only 
in SLNas samples prepared using ST as surfactant or co-surfactant agent. The lowest levels of 
nitrogen atoms were detected in SLNas/F127 owing to the only contribution of RIF close to the sample 
surface. Consequently, the highest nitrogen levels exhibited by the other samples are reasonably 
attributable to the functionalizing/surfactant agents MS and ST located on the particle surface.  
As regards wettability, contact angles less than 90° were measured for all SLNas samples 
revealing that wetting of the surface was favorable (Table 4). The surface wettability is conceivably 
attributable to the hydrophilicity conferred by the surfactants to the hydrophobic nanoparticle lipid 
matrix. The weakest water-wet properties were given by SLNas/F127 in accordance with the values 
assigned to the brush-like conformation adopted on hydrophobic surfaces by the PEO chains of the 
surfactant [58,59]. 
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3.2. Lipid Corona Formation upon SLNas Contact with Pulmonary Surfactant 
Once nanoparticles administered in a dry powder form reach pulmonary alveoli, pulmonary 
surfactant is the first lung component they encounter as a monolayer or oligolamellar layer at the air-
liquid interface of the fluid lining alveoli [60]. Pulmonary surfactant is also present in the case of 
human respiratory infections even if with reduced availability of lipids and proteins [12]. In order to 
evaluate the possible occurrence of interactions between SLNas samples and pulmonary surfactant, 
SLNas were treated with Curosurf, a commercial substitute of the natural pulmonary surfactant, and 
analyzed for size, PDI, zeta potential, and elemental composition. Moreover, the effect of the lipid 
corona around the nanoparticles on in vitro drug release was assessed. 
The interactions between pulmonary surfactant and nanoparticles can be assessed by means of 
changes in size and zeta potential of the nanoparticles. After the treatment with Curosurf, all the 
samples increased significantly (p ≤ 0.05) in size by 1.5 to 5-fold (Table 5), except SLNas/F127 (p > 
0.05). This finding could be presumably related to the insufficient affinity of Curosurf for F127 
functional groups as reported by other authors [23].  
Table 5. Dimensional values (size and PDI) of the SLNas samples before and after treatment with 
Curosurf. Mean values ± SD. 
SLNas Samples 
In Saline Solution In Saline Solution with Curosurf Fold Increase 
in Size Size (nm) PDI Size (nm) PDI 
SLNas/MS 962 ± 286 0.45 ± 0.20 1611 ± 272 0.4 ± 0.2 1.67 
SLNas/MS-ST 356 ± 64 0.29 ± 0.13 1839 ± 90 0.22 ± 0.01 5.17 
SLNas/ST 284 ± 36 0.27 ± 0.04 884 ± 158 0.31 ± 0.02 3.11 
SLNas/F127 551 ± 6 a 0.68 ± 0.05 837 ± 272 a 0.5 ± 0.3 1.52 
a Among lines, superscript indicates no significant difference among the size without Curosurf and 
that with Curosurf from each sample (p > 0.05). 
As regards zeta potential, the negative value exhibited by Curosurf (−32 ± 3 mV) was not 
expected to modify significantly the negative surface charge of SLNas samples and this impaired the 
contribution of such a measurement to corona formation assessment.  
The key role played by the phospholipid fraction in the pulmonary surfactant may justify the 
use of the EDX analysis focused on phosphorous element detection. The elemental analysis 
performed by EDX by means of the single point method provided the semi-quantitative composition 
of each SLNas sample before and after treatment with Curosurf. Moreover, each corresponding 
ESEM image showed, for all the samples treated with Curosurf, the presence of distinct particles 
surrounded by a poorly dense layer ascribable to the pulmonary surfactant. Only few aggregates 
were observed (Figure 4). The presence, in the samples treated with Curosurf, of phosphorous 
belonging exclusively to phospholipids as well as sodium chloride contained in Curosurf saline 
solution was reasonably due to the formation of a phospholipid corona around the particles. 
Phosphorous was detectable in all the SLNas samples, without significant differences among them (p 
< 0.05), with the exception of SLNas/F127 (level below the detection limit of <0.05%) (Table 6). Unlike 
sodium and chlorine X-ray emissions due to both material impurities and ST, phosphorous levels 
were below the detection limit in all the untreated samples (data not shown). Hence, EDX analysis 
further confirms the lipid corona formation due to interactions between the pulmonary surfactant 
substitute and the SLNas surface decorated with both MS and ST. 
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Figure 4. Representative ESEM image with an enlarged frame of a SLNas/MS sample treated with 
Curosurf. 
Table 6. Elemental composition by EDX analysis of pure Curosurf and of SLNas samples treated with 
Curosurf (relative weight %, mean values ± SD). 
Samples C O Na P S Cl 
Curosurf 71 ± 2 22 ± 2 1.1 ± 0.1 4.6 ± 0.6 0.04 ± 0.04 1.6 ± 0.2 
SLNas/MS 85 ± 3 8 ± 1 3 ± 2 0.3 ± 0.1 0.03 ± 0.04 4 ± 2 
SLNas/MS-ST 83 ± 3 8 ± 3 4 ± 3 0.3 ± 0.2 0.01 ± 0.01 5 ± 3 
SLNas/ST 91 ± 1 8 ± 1 0.6 ± 0.2 0.26 ± 0.06 0.02 ± 0.02 0.7 ± 0.2 
SLNas/F127 94.39 ± 0.05 3.94 ± 0.3 0.7 ± 0.1 0.02 ± 0.01 0.01 ± 0.00 0.9 ± 0.2 
3.3. Effect of Pulmonary Surfactant on Drug Release and Macrophage Activity 
Lung surfactant, especially its phospholipid fraction, may impact drug release before AM 
internalization, as well as particle agglomeration, and cellular uptake due to lipid corona formation 
on the SLNas surface [61]. SLNas designed to be taken up by AM should be able to retain most of the 
active principle upon contact with lung fluids until its entry into AM. Based on that, in vitro drug 
release from SLNas samples was evaluated in SLF containing or not Curosurf (Figure 5).  
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Figure 5. Rifampicin release from SLNas/MS (a), SLNas/MS-ST (b), SLNas/ST (c), and SLNas/F127 (d) 
in simulated lung fluid with or without (w/o) the pulmonary surfactant substitute (Curosurf). 
Drug release in pure SLF was gradual from the lipid matrix of mannosylated SLNas (SLNas/MS 
and SLNas/MS-ST; Figure 5a,b) and reached RIF percentages of about 40% in 3 h. In contrast, about 
60% RIF was released from the control samples SLNas/ST and SLNas/F127 (Figure 5c,d). Drug 
retaining capability exhibited by mannosylated samples could be attributed to a closer settlement of 
the functionalizing agent lipophilic tale within the particle lipid phase which may generate a firmer 
SLNas matrix as observed in a previously published research [5]. Therefore drug spreading over the 
lung fluid before AM uptake should not occur for mannosylated SLNas, since 50–75% of inhaled 
particles should be taken up by AM in 2–3 h [47]. RIF release in SLF containing Curosurf decreased 
by 20–25% (p < 0.05) for all the samples, except for SLNas/F127, that is the only sample that proved 
to fail in interacting with the pulmonary surfactant substitute. The observed improvement in drug 
retention, attributable to an additional resistance to drug diffusion provided by lipid corona layer, 
could be considered as an advantage as it leads to a greater amount of drug available within the lipid 
matrix to be transported into AM. After AM phagocytosis, lipid materials are known to be degraded 
inside macrophages by lipolytic enzymes, allowing drug intracellular leakage and antibacterial 
activity [62]. 
Besides the conflicting results concerning the effects of protein/lipid corona on biological 
interactions between nanoparticles and cells, it is reasonable to expect that the activity generated by 
the surface chemistry of particles coated by the pulmonary surfactant layer might undergo some 
changes upon contact with AM membrane and its MR. Consequently, the effect of the pulmonary 
surfactant layer on SLNas ability to be phagocytosed with or without impact on MR interactions was 
investigated on MH-S cell line, referred as an in vitro model similar to human primary cells [63]. All 
the samples and pure RIF were preliminarily subjected to cytotoxicity test according to the incubation 
time. 
SLNas cytotoxicity was investigated at increasingly sample amounts (from 0.125 to 1 mg/mL) 
and a significant dose-dependent cell cytotoxicity was found for the mannosylated SLNas samples 
starting from the dose of 0.5 mg/mL (p < 0.05) (Figure 6a).  
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Figure 6. Cytotoxicity of SLNas samples at 6 h incubation time (a) and pure rifampicin at 24 h 
incubation time (b) determined on MH-S cell line. Dotted line as the control. Significance was 
indicated by * p <0.05, ** p < 0.01, *** p < 0.005. 
Since excipient concentrations and RIF loading levels are recognized as safe (non-cytotoxic) in 
the obtained SLNas (Figure 6b), the dose-dependent cell apoptosis could be reasonably attributed to 
the increase of particle amounts [64] or particle clustering phenomena [65,66]. With respect to 
SLNas/F127, such an effect may have been precluded by F127 surfactant recognized to be capable of 
inhibiting nanoparticle cell adhesion [67]. 
Based upon the cytotoxicity results, the study of SLNas macrophage internalization was 
performed on 0.25 mg/mL SLNas dose, corresponding to about 22.5 μg/mL RIF for all the samples, 
that is higher than the minimum inhibitory concentration against Mycobacterium tuberculosis strain (1 
μg/mL) [68]. Intracellular RIF concentrations were determined on SLNas samples up to an incubation 
time of 3 h that is considered consistent with both AM phagocytosis rate [47,69] and the occurrence 
of intracellular RIF [5]. The internalization data were compared with those obtained following both 
MR inhibition and pulmonary surfactant co-treatment (Figure 7).  
 
Figure 7. Intramacrophagic rifampicin percentages upon cell exposure to SLNas samples in 
comparison with those determined following both cell mannose receptor inhibition and co-treatment 
with pulmonary surfactant substitute (Curosurf). SLNas/MS (a), SLNas/MS-ST (b), SLNas/ST (c), and 
SLNas/F127 (d). Significance was indicated by * p < 0.05, ** p < 0.01, *** p < 0.005. 
Fast and complete drug translocation within AM was achieved by cell exposure to SLNas/MS 
and reached 100% intramacrophagic RIF at 0.5 h incubation (Figure 7a). This maximum drug 
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concentration was maintained intracellularly until drug degradation occurs, leading to a 
concentration decrease by one-half at 3 h incubation (p < 0.05). Conversely, SLNas/MS-ST sample 
behaved as the controls SLNas/ST and SLNas/F127 and showed RIF translocation values less than 
50%, regardless of the incubation time (Figures 7b–d). The greatest internalization ability of 
SLNas/MS is therefore the consequence of SLNas mannose recognition by MR, which are highly 
expressed on MH-S cell line [70]. By contrast, ST seemed to not contribute to AM internalization 
through mechanisms of active targeting. Comparison between drug translocation efficiency provided 
by SLNas/MS and that by SLNas/MS-ST therefore gives an indication of the key role played by 
mannose density on nanoparticle surface [71]. MR-mediated uptake by macrophages was 
investigated by cell pre-treatment with D-mannose to saturate the corresponding receptors [5,72,73]. 
MR inhibition resulted in a relevant decrease (about 50%) of intracellular RIF only by cell exposure 
to SLNas/MS at 0.5 h (p < 0.005) and at 1 h (p < 0.01), before drug degradation occurrence at 3 h 
incubation (Figure 7a), confirming the considerable contribution from the active targeting process. 
Otherwise, RIF transport across macrophage membrane was only slightly affected (10% intracellular 
RIF decrease) by MR inhibition upon cell contact with SLNas/MS-ST (p < 0.05 at 1 and 3 h; Figure 7b) 
and SLNas/ST (p < 0.05 at 3 h; Figure 7c), suggesting a marginal contribution from MR-mediated cell 
uptake. Insignificant changes in RIF translocation were detected for SLNas/F127 (p > 0.05; Figure 7d), 
regardless of the incubation time. It follows that a passive targeting could be assumed as the main 
mechanism for the macrophage uptake of these latest SLNas samples.  
Concerning the effect of pulmonary surfactant on SLNas cell uptake, the interactions between 
mannose groups on SLNas/MS surface and macrophage MR were negligibly impaired by the 
presence of the pulmonary surfactant substitute, regardless of the incubation time (p > 0.05) (Figure 
7a). This finding suggests that the adsorbed lipid corona layer does not completely mask the 
functional groups on nanoparticle surface as observed also by other authors [74]. Corona formation 
appeared instead to promote macrophage internalization when passive targeting regulates the 
process, i.e. for SLNas/MS-ST and SLNas/ST samples, leading in general to increased RIF intracellular 
concentrations (from about 10 to 20%) (p < 0.05; Figure 7b,c). Different mechanisms could be 
hypothesized for an increased intracellular uptake generated by pulmonary surfactant coating on 
nanoparticles, including recognition promotion by macrophages and hydrophobic interactions or 
fusion between nanoparticle surface and macrophage membrane similarly to the process involving 
liposomes [31]. The lack of a significant uptake modification provided by pulmonary surfactant on 
SLNas/F127 (p > 0.05) proved further the absence of lipid corona.  
4. Conclusions 
In previous researches, SLNas functionalized by a mannosylated surfactant for tuberculosis 
inhalation therapy were implemented in terms of production technique and active targeting to 
alveolar macrophages. The successful results thus achieved encouraged the present investigation that 
deals with the effect of pulmonary surfactant on drug translocation within alveolar macrophages. 
Even though our findings demonstrated that mannose functional groups interact with pulmonary 
surfactant, their density on SLNas surface influences both drug receptor-mediated transport into 
macrophages and the intramacrophagic transport promoted by the lipid corona. These results 
highlight the need for specific studies according to each modification introduced on the surface of 
inhaled carriers designed to be taken up by alveolar macrophages. Further studies to address in vivo 
drug targeting potentiality and bio-distribution on animal models are ongoing. 
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